Pregabalin Capsule
Product Images NDC 70518-2745

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2745). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin 100mg 70518 2745 01

Label for Pregabalin 100 mg oral capsules, repackaged by RemedyRepack Inc. The label indicates a quantity of 60 capsules and categorizes the product as C-V. Manufacturer is Novadoz Pharmaceuticals LLC, Piscataway, NJ. Includes storage instructions, a QR code, and directions to see the package insert.*

FDA Label Image

Remedy_label (Remedy Label)

Pregabalin 100 mg capsule label by Remedy Repack Inc. The label indicates a quantity of 90 capsules and a schedule of C-V. It includes manufacturer information listing Novadoz Pharmaceuticals LLC in Piscataway, NJ. Additional details include storage instructions and a QR code on the right side.*

FDA Label Image

Equation (Pregabain Gault Equation)

Formula showing creatinine clearance calculation with age, weight in kg, serum creatinine in mg/dL, and an adjustment factor for female patients. The formula is presented as part of a drug information panel.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, depicting the efficacy of different doses over a range of pain improvement percentages.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A Kaplan-Meier-type plot showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg taken three times a day (dashed line) to placebo (dotted line), illustrating a higher percentage of patients improved with Pregabalin across various levels of pain improvement.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline with Pregabalin treatment. Four lines represent different dosing regimens: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and Placebo. The graph illustrates how the percentage of patients improved decreases as pain improvement increases across these groups.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier plot showing the percent of patients improved relative to percent improvement in pain from baseline. The curve compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, illustrating the distribution of patient pain improvements across these treatments.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A Kaplan-Meier curve showing the percent of patients improved plotted against percent improvement in pain from baseline. The graph compares three groups: Pregabalin 100 mg three times a day (dashed line), Pregabalin 50 mg three times a day (solid line), and placebo (dotted line). The y-axis represents the percent of patients improved, ranging from 0 to 100%, while the x-axis shows percent improvement in pain from greater than 0 to 100%.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart titled Study E1 and Study E3 showing responder rates (%) on the vertical axis and different treatment groups on the horizontal axis, including placebo and various dosages of Pregabalin oral capsules. The chart compares responder rates across doses administered twice daily (BID) or thrice daily (TID), with numerals and sample sizes indicated below each group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

This figure is a line chart depicting seizure reduction, represented as median percentage change from baseline, plotted against dosage in mg/day. It includes data series labeled as Stukly E1BID, E2BID, E3BID, and E3TID, with significance p-values indicated for various doses. The chart shows a dose-dependent increase in seizure reduction up to 600 mg/day.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A Kaplan-Meier style curve graph showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. Four lines represent Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, depicting comparative patient improvement across these treatment groups.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve chart depicting the estimated percentage of subjects without LTR over a 180-day period. Two lines are shown: a solid line for Pregabalin and a dashed line for Placebo, illustrating differences in subject outcomes over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph showing the percent of subjects improved on the vertical axis and percent improved from baseline to Week 12 on the horizontal axis, comparing Pregabalin (solid line) and Placebo (dotted line). The graph illustrates the improvement trends over various percentage thresholds.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph comparing the percent of subjects improved versus percent improved from baseline to week 16 for Pregabalin and placebo groups. The x-axis shows the percent improved from baseline to week 16 BOCF, and the y-axis shows the percent of subjects improved. Two lines are shown: a solid line for Pregabalin and a dashed line for placebo, depicting the distribution of improvement percentages among subjects.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure diagram of Pregabalin, showing its molecular arrangement including amino, carboxyl, and alkyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.